The clinical utility of NGS panel testing: Identifying PIK3CA, AKT1, and/or PTEN-altered HR+/HER2- advanced breast cancer that may be eligible for treatment with TRUQAP™ (capivasertib) + fulvestrant following progression on or after ET ± CDK4/6i*1